Uchani, Karnal, Haryana
Send E-mail

Pharmaceutical Capsule

We are one of the leading manufacturers, exporters and suppliers of quality range of Capsule. Accurately processed using high grade chemical compounds and advanced technology in compliance with set quality standards, our offered range is also thoroughly quality tested at each step of processing. The offered range is in great demand for treatment of various ailments due to properties such as high quality, effective result and no side effects. Through price-competitiveness, our clients experience optimum level of satisfaction.

Request Callback
Lanzee 30 Capsule

Ask For Price

Lanzee 30 Capsule

Lanzee-30 capsules

(lansoprazole delayed release capsules u. S. P. ) 


Each Capsule Contains:

Lansoprazole  u. S. P.   30 mg.

(as enteric coated granules)

 Pharmacological action:

Lansoprazole is a specific proton pump (h+, k+ - atpase) inhibitor of the gastric parietal cell.

Due to its mechanism of action, lansoprazole reduces gastric acid secretion whatever the nature of the stimulation. Lansoprazole causes rapid, effective and lasting inhibition of gastric acid secretion. This inhibition is dose-dependent. Gastric secretory functions recover gradually after the end of treatment. Lansoprazole has no effect on histamine, acetylcholine and gastrin receptors.

In a single dose study, 30 mg of lansoprazole reduced the acid concentration by 81% after 2 hours. In a multiple dose study, 30 mg of lansoprazole administered once daily has been shown to inhibit basal acid output by 72% on the first day of treatment and by 87% after seven days of treatment. The inhibition of the pentagastrin stimulated acid output is 81% on the first day of treatment and 90% after seven days of treatment.


The absolute bioavailability of lansoprazole from a single oral dose of 30 mg lanzee is approximately 78%. The pharmacokinetic parameters revealed no statistically significant differences between day 1 and day 7 after repeated doses with regard to cmax, tmax, auc or half-life.

Bioavailability of lansoprazole is decreased if administered with food.

Absorption and distribution:

As lansoprazole is unstable in acid, it is administered orally in the form of enteric-coated granules in capsules. Absorption is rapid with the maximum serum concentration being achieved within approximately 1½ hours. The protein binding of lansoprazole is 97%.


The plasma elimination half-life is 1,4 hours. This does not alter during treatment. Lansoprazole is metabolised mainly in the liver. The sulphone, sulphide and 5-hydroxyl derivatives of lansoprazole have been identified in the plasma. These metabolites do not have notable activity or toxicity.

Lanzee 30 is indicated for the short-term treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis.

Lansoprazole is indicated for h. Pylori positive duodenal ulcers, as part of the eradication programme with appropriate .


Hypersensitivity to lansoprazole.

Pregnancy and lactation.

Patients with liver impairment.

Dosage and directions for use:

The recommended once daily dosage should preferably be administered before a meal.

Duodenal ulcer:

One 30 mg capsule per day for 2-4 weeks.

Lansoprazole is indicated for h. Pylori positive duodenal ulcers, as part of the eradication programme with appropriate .

Qastric ulcer:

One 30 mg capsule per day for 8 weeks.

Oesophagitis due to gastro-oesophageal reflux:

One 30 mg capsule per day for 4 weeks with a second 4-week treatment period, at the same dosage, depending on endoscopic results.

Storage Instructions:

Store in a cool, dry place, below 25°c

Yes! I am interested

Tell Us What You Are Looking For?

Reach Us


Zee Laboratories Limited Uchani, G. T. Road,
Karnal - 132001, Haryana, India

Ashok Sharma ( General Manager- Exports )
Send SMS

Share Us:

Competitive Quotes
Choice of Suppliers